Pfizer Restructuring charges and certain acquisition-related costs decreased by 83.4% to $100.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 85.3%, from $678.00M to $100.00M. Over 3 years (FY 2022 to FY 2025), Restructuring charges and certain acquisition-related costs shows an upward trend with a 4.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Higher costs indicate active organizational transformation or M&A integration, whereas lower costs suggest a period of operational stability.
This metric aggregates expenses incurred from organizational restructuring initiatives and costs directly associated wit...
Frequently disclosed by companies undergoing significant M&A or cost-reduction programs to highlight non-recurring operational impacts.
is_pfe_restructuring_and_acquisition_costs| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $140.00M | $764.00M | $280.00M | $345.00M | $357.00M | $393.00M | $107.00M | $313.00M | $155.00M | $2.37B | $168.00M | $1.25B | $313.00M | $684.00M | $678.00M | -$18.00M | $286.00M | $604.00M | $100.00M |
| QoQ Change | — | +445.7% | -63.4% | +23.2% | +3.5% | +10.1% | -72.8% | +192.5% | -50.5% | >999% | -92.9% | +646.4% | -75.0% | +118.5% | -0.9% | -102.7% | >999% | +111.2% | -83.4% |
| YoY Change | — | — | — | +146.4% | -53.3% | — | -61.8% | -9.3% | -56.6% | +502.5% | +57.0% | +300.6% | +101.9% | -71.1% | +303.6% | -101.4% | -8.6% | -11.7% | -85.3% |